Structures of enzymatically modified products of arbekacin by methicillin-resistant. Staphylococcus aureus.
Only a limited number of strains of methicillin-resistant Staphylococcus aureus (MRSA) moderately resistant to arbekacin (ABK) have been isolated clinically. Three inactivated products of ABK have been obtained by reaction with excess amounts of a crude enzyme preparation extracted from an ABK-resistant MRSA strain (MIC, 25 micrograms/ml). The 2"-O-phosphate was the major product together with small amounts of the 6'-N-acetate and the double modification product. The structures of these modification products were determined by MS and NMR spectral analyses.
Kondo
S
S
Institute of Microbial Chemistry, Tokyo, Japan.
Tamura
A
A
Gomi
S
S
Ikeda
Y
Y
Takeuchi
T
T
Mitsuhashi
S
S
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D008658:Inactivation, Metabolic; D009682:Magnetic Resonance Spectroscopy; D016106:Methicillin Resistance; D013211:Staphylococcus aureus / Q000187:drug effects / Q000378:metabolism*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin; C031986:arbekacin